Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Afatinib in Advanced NRG1-Rearranged Malignancies: the NCT/DKTK PMO-1604 Phase-II Trial

NCT04410653 is registered in ClinicalTrials.gov with German Cancer Research Center as lead sponsor.

NCT NCT04410653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04410653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Afatinib in Advanced NRG1-Rearranged Malignancies: the NCT/DKTK PMO-1604 Phase-II Trial
Lead sponsor
German Cancer Research Center
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2022
Completion date
October 4, 2023
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic and locally advanced nrg1-rearranged malignancies